Leukemia

Be The Match Announces Winners of 2023 NMDP/Be The Match Awards

Retrieved on: 
Monday, November 27, 2023

MINNEAPOLIS, Nov. 27, 2023 (GLOBE NEWSWIRE) -- National Marrow Donor Program (NMDP)/Be The Match®, today announced the recipients of its annual NMDP/Be The Match Awards at The ONE Forum 2023.

Key Points: 
  • MINNEAPOLIS, Nov. 27, 2023 (GLOBE NEWSWIRE) -- National Marrow Donor Program (NMDP)/Be The Match®, today announced the recipients of its annual NMDP/Be The Match Awards at The ONE Forum 2023.
  • The awards honor individuals, groups, NMDP/Be The Match Network members or organizations working to increase awareness or access to potentially life-saving cell therapy.
  • The 2023 NMDP/Be The Match Award recipients are:
    Dr. Mukherjee’s idea for a new approach to cancer treatment led to groundbreaking research that has the potential to transform outcomes for patients with AML and other blood cancers.
  • “We are honored to celebrate and acknowledge the contributions of this year’s NMDP/Be The Match Award winners,” said Amy Ronneberg, Chief Executive Officer for NMDP/Be The Match.

Global Menin Inhibitor Drugs Clinical Trials & Future Opportunity Insight 2023: A New Generation of Proteins that have Found Application as a Therapeutic Target in Several Prevalent Diseases - ResearchAndMarkets.com

Retrieved on: 
Thursday, December 21, 2023

The "Global Menin Inhibitor Drugs Clinical Trials & Future Opportunity Insight 2023" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global Menin Inhibitor Drugs Clinical Trials & Future Opportunity Insight 2023" report has been added to ResearchAndMarkets.com's offering.
  • Menin represents a new generation of proteins that have found application as a therapeutic target in several prevalent diseases, especially cancer.
  • This has generated the need for development of menin inhibitors that can be used to treat these diseases.
  • Global Menin Inhibitor Drugs Clinical Trials & Future Opportunity Insight 2023 Report Highlights:
    Menin Inhibitors Drugs In Clinical Trials: > 10 Drugs
    Global Menin Inhibitors Drugs Clinical Trials By Company, Indication & Phase
    Menin Inhibitors Clinical Research Innovation Trends By Region: US, Europe & Canada

Baron & Budd Announces Fall 2023 Mesothelioma Cancer Victims Memorial Scholarship Winner

Retrieved on: 
Monday, December 18, 2023

Today, the national law firm of Baron & Budd announced that it has selected Taylor Hay as the winner of the Mesothelioma Cancer Victims Memorial Scholarship .

Key Points: 
  • Today, the national law firm of Baron & Budd announced that it has selected Taylor Hay as the winner of the Mesothelioma Cancer Victims Memorial Scholarship .
  • Taylor Hay’s winning written essay was selected after a competitive review by the Baron & Budd Scholarship committee.
  • The Mesothelioma Cancer Victims Memorial Scholarship was established to honor the legacy of the thousands of Americans who are diagnosed with mesothelioma cancer every year.
  • For more information about the Baron & Budd Mesothelioma Cancer Victims Memorial Scholarship, please visit baronandbudd.com/mesothelioma-lawyer/scholarships/ .

The Ehlers-Danlos Society Receives $6.7 Million from the Mike and Sofia Segal Foundation to Advance Cutting-Edge Research for Ehlers-Danlos Syndrome

Retrieved on: 
Wednesday, December 20, 2023

NEW YORK, Dec. 20, 2023 /PRNewswire/ -- The Ehlers-Danlos Society, the global non-profit dedicated to advancing and accelerating research in the Ehlers-Danlos syndromes (EDS) and hypermobility spectrum disorders (HSD), today announced it has received a $6.7 million funding commitment from the Mike and Sofia Segal Foundation (the "Foundation") to advance its groundbreaking research initiatives.

Key Points: 
  • The support from the Mike and Sofia Segal Foundation is invaluable in propelling our research towards earlier diagnosis.
  • In 1978, Mike and Sofia Segal arrived in the U.S. from present-day Ukraine with $120, a young child, and just two suitcases.
  • The partnership between the Ehlers-Danlos Society and the Foundation marks a significant leap forward in the quest for breakthroughs in EDS and HSD research.
  • The Ehlers-Danlos Society and the Foundation hope this investment will serve as a catalyst, inspiring related contributions and collaborations within the scientific community and beyond.

Vittoria Biotherapeutics Secures Over $15 Million in Private Financing Round to Support the Development of Novel CAR-T Cell Therapies

Retrieved on: 
Tuesday, November 14, 2023

PHILADELPHIA, Nov. 14, 2023 (GLOBE NEWSWIRE) -- Vittoria Biotherapeutics today announced it has secured over $15 million in a private financing round.

Key Points: 
  • PHILADELPHIA, Nov. 14, 2023 (GLOBE NEWSWIRE) -- Vittoria Biotherapeutics today announced it has secured over $15 million in a private financing round.
  • The funds will be used to continue advancing Vittoria’s lead candidate, VIPER-101, an autologous, dual population CD5-knockout CAR-T cell therapy for T-cell Lymphoma, into the clinic.
  • The additional capital will support Vittoria’s clinical development initiatives and advance its next-generation cell therapies that strengthen efficacy, improve safety, and broaden therapeutic applicability for patients with cancer and autoimmune diseases.
  • By acting on the fundamental biology of T cells, Senza5 can be widely utilized to improve the efficacy of engineered T-cell therapies.

SELLAS Life Sciences Receives Favorable FDA Type C Meeting Feedback on Chemistry, Manufacturing, and Controls (CMC) Biologics License Application (BLA) Filing Strategy for Galinpepimut-S (GPS)

Retrieved on: 
Monday, November 13, 2023

NEW YORK, Nov. 13, 2023 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) (“SELLAS” or the “Company”), a late-stage clinical biopharmaceutical company focused on the development of novel therapies for a broad range of cancer indications, today announced that it recently concluded a Type C meeting with the U.S. Food and Drug Administration (FDA) regarding the Company’s Chemistry, Manufacturing, and Controls (CMC) sections in a potential biologics license application (“BLA”) for SELLAS’ lead product candidate, galinpepimut-S (GPS). SELLAS submitted a CMC Briefing Package to the FDA which provided an up-to-date overview of the extensive work completed for the GPS CMC program and commercial manufacturing and regulatory plans. The FDA reviewed this package of data and accompanying questions to the agency and responded with favorable guidance.

Key Points: 
  • SELLAS submitted a CMC Briefing Package to the FDA which provided an up-to-date overview of the extensive work completed for the GPS CMC program and commercial manufacturing and regulatory plans.
  • The FDA reviewed this package of data and accompanying questions to the agency and responded with favorable guidance.
  • GPS is expected to be stored at 2-8 C (36 – 46 F) making it more accessible for end-users.
  • GPS has the potential to offer clinical benefit to this population of leukemia patients and the positive CMC regulatory feedback is a critical step in its development.”

Children with cancer evacuated from Gaza for treatment to Egypt and Jordan

Retrieved on: 
Friday, November 10, 2023

Additional children are expected to be evacuated for cancer treatment as part of this initiative.

Key Points: 
  • Additional children are expected to be evacuated for cancer treatment as part of this initiative.
  • “I am relieved that children in vital need of cancer care have been able to leave the insecurity and uncertainty in Gaza and continue receiving life-saving treatment in Egypt and Jordan,” said Dr Tedros Adhanom Ghebreyesus, the WHO Director-General.
  • Cancer care services are therefore severely limited, meaning it is critically urgent to transfer patients outside Gaza for treatment.
  • But these children receive only a portion of their cancer care within Gaza due to lack of some cancer services, and, therefore, require referrals to hospitals in the West Bank, including East Jerusalem, Egypt, Israel and Jordan for further treatment.

Vor Bio Presents Positive Data Update on Trem-cel at HSCT² Conference

Retrieved on: 
Thursday, November 9, 2023

Additionally, platelet recovery occurred at a median of 15.5 days, excluding one patient with previously documented anti-platelet antibodies (immune thrombocytopenia).

Key Points: 
  • Additionally, platelet recovery occurred at a median of 15.5 days, excluding one patient with previously documented anti-platelet antibodies (immune thrombocytopenia).
  • This data further validates Vor Bio’s approach of using transplant donor cells as CAR-T starting material that are healthy, stem-like, and exactly matched to the patient’s immune system.
  • Vor Bio management will host a live webcast today at 4:30 PM ET.
  • A replay of the webcast will be available via the investor section of the Company’s website at www.vorbio.com approximately two hours after the call’s conclusion.

IN8bio Reports Third Quarter 2023 Financial Results and Provides Corporate Update

Retrieved on: 
Thursday, November 9, 2023

Updated Phase 1 clinical data from INB-200 to be presented at Society for Neuro-Oncology (SNO) on November 17, 2023.

Key Points: 
  • Updated Phase 1 clinical data from INB-200 to be presented at Society for Neuro-Oncology (SNO) on November 17, 2023.
  • NEW YORK, Nov. 09, 2023 (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB), a leading clinical-stage biopharmaceutical company developing innovative gamma-delta T cell therapies, today announced financial results, operational highlights and recent corporate developments for the third quarter ended September 30, 2023.
  • The presentation at ASH will highlight clinical data updating the efficacy results of INB-100 including complete responses (CRs) and durability.
  • Cash: As of September 30, 2023, the Company had cash of $12.9 million, compared to $17.0 million as of June 30, 2023.

Global CD3 Antibodies Market, Dosage, Price, & Sales Report 2023-2028: $5 Billion Opportunity, Clinical Trials Insights on 250 Antibodies, and 9 Commercially Approved CD3 Antibodies - ResearchAndMarkets.com

Retrieved on: 
Friday, December 15, 2023

The "Global CD3 Antibodies Market, Dosage, Price, Sales & Clinical Trials Insight 2028" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global CD3 Antibodies Market, Dosage, Price, Sales & Clinical Trials Insight 2028" report has been added to ResearchAndMarkets.com's offering.
  • However, both these CD3 antibodies were withdrawn from the market for different clinical and commercial reasons, but, nevertheless, positioned themselves as pioneers of the CD3 antibodies market.
  • Among these is the global market value of CD3 antibodies, which has been increasing every quarter as new antibodies are approved and introduced into the market.
  • Global CD3 Antibodies Market, Dosage, Price, Sales & Clinical Trials Insight 2028 Report Highlights:
    Global CD3 Antibodies Market Opportunity: > USD 5 Billion By 2028
    CD3 Antibodies Clinical Trials Insight By Company, Country, Indication & Phase